CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2012 ASCO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Joseph Unger on Low-Income Clinical Trial Participation
Dr. Taplin on Abiraterone Acetate's Mechanism of Action
Dr. Ryan on Neoadjuvant Abiraterone Acetate
Oncology Conference Articles
Two Newer Breast Cancer Therapies Not Superior to Standard Paclitaxel, Study Suggests
The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.
Study Finds Cymbalta Reduces Peripheral Neuropathy Pain
The antidepressant duloxetine relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients.
Pilot Study Evaluates a Proposed Quality Measure for Family History Collection and Genetic Testing Referral
Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.
FDA and Industry Collaborating to Prevent Cancer Drug Shortages
Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.
Two New BRAF-Targeted Therapies Reduce Disease Progression in Advanced Melanoma Patients
Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.
Regorafenib Offers New Hope for Patients With Treatment-Resistant GIST
The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.
Afatinib Prolongs PFS in Lung Cancer Trial
Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.
Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients
Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.
Antibody Drug Conjugate T-DM1 Improves PFS in HER2-Positive Breast Cancer
T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.
Bendamustine Superiority in Lymphoma Regimen Confirmed
Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.
With Continuous Hormonal Therapy, Certain Men With Prostate Cancer Get Marked Boost in Survival
Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.
Avastin Delays Disease Progression in Platinum-Resistant Ovarian Cancer
Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.
Patients With Metastatic Kidney Cancer Prefer Pazopanib Over Sunitinib, Study Shows
Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.
Large Study of ALL Patients Finds Lower Survival in Adolescent and Young Adult Patients
Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.
PD-1 Immunotherapy Makes Strong Showing in Three Tumor Types
An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.
Analysts, Companies Highlight Key ASCO Research
Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.
Advanced Coverage Recap: 2012 ASCO Annual Meeting
On May 16, the ASCO highlighted the results of five ground-breaking studies in advance of its annual meeting held in Chicago from June 1-5, 2012.
Neoadjuvant Zytiga Helps Eliminate Some Patients' Prostate Tumors
Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.
Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations
A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.
Olanzapine Proves Effective in Breakthrough CINV
Olanzapine, an antipsychotic medication that is often used off-label, has proved highly effective in controlling breakthrough chemotherapy-induced nausea and vomiting.
PCPs Highly Unaware of Long-Term Chemotherapy Side Effects
Many primary care providers and some oncologists are unaware of the long-term effects of four chemotherapy drugs used to treat two of the most common forms of cancer.
Crizotinib Active in ALK-Positive Pediatric Cancers
Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.
Preview: 2012 ASCO Annual Meeting Coverage
OncLive.com will be on-site at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
FDA Approvals in Cervical Cancer, Ovarian Cancer, and CLL, and More
Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma
Upfront Options Continue to Expand in Ovarian Cancer
Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL
Neratinib/T-DM1 Combo Shows Promise in HER2-Positive Breast Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.